Conditions: Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 31
Healthy volunteers: no

Brief summary:
This study was conducted: 1) to assess the clinical effect of Navarixin on the Psoriasis Activity and Severity Index (PASI), 2) to determine the effects of Navarixin on the Physician's Global Assessment (PGA), 3) to evaluate the safety and tolerability of Navarixin, and 4) to determine the multiple-dose pharmacokinetics of Navarixin.

Detailed description:

Arms:
arm 1: Navarixin 30 mg administered orally once daily for 28 days. arm 2: Matching placebo to Navarixin administered orally once daily for 28 days.

Interventions: intervention 1: Navarixin 10 mg intervention 2: Placebo
Intervention descriptions: intervention 1: Navarixin capsules orally, once daily for 28 days. intervention 2: Matching placebo capsules to Navarixin orally, once daily for 28 days.

Protocol document: